Half-year report · HY

Period2025-04-01 → 2025-09-30
Filed2025-11-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥17.9bn2025-04-01 → 2025-09-30Cons.Net sales
Revenue¥39.4bn2024-04-01 → 2025-03-31Cons.Net sales (5-year summary)
Revenue¥20.2bn2024-04-01 → 2024-09-30Cons.Net sales
Operating income−¥557m2025-04-01 → 2025-09-30Cons.Operating income
Operating income¥2.5bn2024-04-01 → 2024-09-30Cons.Operating income
Ordinary income¥531m2025-04-01 → 2025-09-30Cons.Ordinary income
Ordinary income¥1.9bn2024-04-01 → 2025-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.4bn2024-04-01 → 2024-09-30Cons.Ordinary income
Profit before tax¥361m2025-04-01 → 2025-09-30Cons.Income before income taxes
Profit before tax¥2.4bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Net income (owners)¥229m2025-04-01 → 2025-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥1.2bn2024-04-01 → 2025-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.9bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income¥229m2025-04-01 → 2025-09-30Cons.Profit loss
Net income¥1.9bn2024-04-01 → 2024-09-30Cons.Profit loss
Total assets¥81.9bnat 2025-09-30Cons.Assets
Total assets¥83.9bnat 2025-03-31Cons.Assets
Total assets¥84.4bnat 2024-09-30Cons.Total assets (5-year summary)
Total liabilities¥9.7bnat 2025-09-30Cons.Liabilities
Total liabilities¥10.7bnat 2025-03-31Cons.Liabilities
Net assets / equity¥72.2bnat 2025-09-30Cons.Net assets
Net assets / equity¥73.2bnat 2025-03-31Cons.Net assets
Net assets / equity¥75.3bnat 2024-09-30Cons.Net assets (5-year summary)
Cash and deposits¥9.1bnat 2025-09-30Cons.Cash and deposits
Cash and deposits¥15.1bnat 2025-03-31Cons.Cash and deposits
Cash & equivalents¥12.3bnat 2025-09-30Cons.Cash and cash equivalents
Cash & equivalents¥18.3bnat 2025-03-31Cons.Cash and cash equivalents
Cash & equivalents¥19.8bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥18.7bnat 2024-03-31vCons.Cash and cash equivalents
Operating cash flow−¥1.3bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥4.4bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥3.0bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥3.6bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥3.5bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥838m2025-04-01 → 2025-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥1.6bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥732m2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥4.212025-04-01 → 2025-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥22.252024-04-01 → 2025-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥35.392024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio88.2%at 2025-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio87.3%at 2025-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio89.2%at 2024-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
LALreportable segmentrevenue2025-04-01 → 2025-09-30¥5.8bn
LALreportable segmentrevenue external2025-04-01 → 2025-09-30¥5.8bn
LALreportable segmentsegment profit2025-04-01 → 2025-09-30¥178m
Pharmaceuticalreportable segmentrevenue2025-04-01 → 2025-09-30¥12.1bn
Pharmaceuticalreportable segmentrevenue external2025-04-01 → 2025-09-30¥12.1bn
Pharmaceuticalreportable segmentsegment profit2025-04-01 → 2025-09-30−¥735m
—segment totalrevenue2025-04-01 → 2025-09-30¥17.9bn
—segment totalrevenue external2025-04-01 → 2025-09-30¥17.9bn
—segment totalsegment profit2025-04-01 → 2025-09-30−¥557m
LALreportable segmentrevenue2024-04-01 → 2024-09-30¥5.9bn
LALreportable segmentrevenue external2024-04-01 → 2024-09-30¥5.9bn
LALreportable segmentsegment profit2024-04-01 → 2024-09-30¥481m
Pharmaceuticalreportable segmentrevenue2024-04-01 → 2024-09-30¥14.3bn
Pharmaceuticalreportable segmentrevenue external2024-04-01 → 2024-09-30¥14.3bn
Pharmaceuticalreportable segmentsegment profit2024-04-01 → 2024-09-30¥2.1bn
—segment totalrevenue2024-04-01 → 2024-09-30¥20.2bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥20.2bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥2.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 528
ItemContextValueUnit
Foreign currency translation adjustmentPrior1YearInstant5643000000JPY
Foreign currency translation adjustmentInterimInstant4492000000JPY
Remeasurements of defined benefit plansPrior1YearInstant1148000000JPY
Remeasurements of defined benefit plansInterimInstant1081000000JPY
Valuation and translation adjustmentsPrior1YearInstant11864000000JPY
Valuation and translation adjustmentsInterimInstant11494000000JPY
Net assetsPrior1YearInstant73187000000JPY
Net assetsInterimInstant72243000000JPY
Liabilities and net assetsPrior1YearInstant83872000000JPY
Liabilities and net assetsInterimInstant81929000000JPY
Net salesPrior1InterimDuration20210000000JPY
Net salesInterimDuration17910000000JPY
Cost of salesPrior1InterimDuration9488000000JPY
Cost of salesInterimDuration10706000000JPY
Gross profitPrior1InterimDuration10721000000JPY
Gross profitInterimDuration7204000000JPY
Personal expenses sgaPrior1InterimDuration1760000000JPY
Personal expenses sgaInterimDuration1666000000JPY
Provision for bonuses sgaPrior1InterimDuration201000000JPY
Provision for bonuses sgaInterimDuration198000000JPY
Retirement benefit expenses sgaPrior1InterimDuration48000000JPY
Retirement benefit expenses sgaInterimDuration55000000JPY
Research and development expenses sgaPrior1InterimDuration3243000000JPY
Research and development expenses sgaInterimDuration3027000000JPY
Other sgaPrior1InterimDuration2930000000JPY
Other sgaInterimDuration2813000000JPY
Selling general and administrative expensesPrior1InterimDuration8184000000JPY
Selling general and administrative expensesInterimDuration7761000000JPY
Operating incomePrior1InterimDuration2537000000JPY
Operating incomeInterimDuration-557000000JPY
Interest income noiPrior1InterimDuration86000000JPY
Interest income noiInterimDuration47000000JPY
Dividends income noiPrior1InterimDuration217000000JPY
Dividends income noiInterimDuration259000000JPY
Foreign exchange gains noiPrior1InterimDuration-JPY
Foreign exchange gains noiInterimDuration51000000JPY
Gain on sales of investment securities noiPrior1InterimDuration-JPY
Gain on sales of investment securities noiInterimDuration633000000JPY
Reversal of environmental measures noiPrior1InterimDuration-JPY
Reversal of environmental measures noiInterimDuration73000000JPY
Other noiPrior1InterimDuration28000000JPY
Other noiInterimDuration34000000JPY
Non operating incomePrior1InterimDuration332000000JPY
Non operating incomeInterimDuration1100000000JPY
Interest expenses noePrior1InterimDuration2000000JPY
Interest expenses noeInterimDuration2000000JPY
Foreign exchange losses noePrior1InterimDuration499000000JPY
Foreign exchange losses noeInterimDuration-JPY
Commission fee noePrior1InterimDuration2000000JPY
Commission fee noeInterimDuration2000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2025-03-31pass
balance sheet identityconsolidated 2025-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2025-03-31pass
statement vs summary · net assetsconsolidated 2025-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2025-04-01/2025-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2025-04-01/2025-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2025-04-01/2025-09-30pass
statement vs summary · total assetsconsolidated 2025-03-31pass
statement vs summary · total assetsconsolidated 2025-09-30pass